Immunotherapy as maintenance treatment in metastatic triple negative breast cancer

被引：1

作者：

Tan, Tira J. ^{[1
]}

Chan, Jack J. ^{[1
]}

Dent, Rebecca A. ^{[1
]}

机构：

[1] Natl Canc Ctr, Div Med Oncol, 11 Hosp Crescent, Singapore 169610, Singapore

来源：

JOURNAL OF CANCER METASTASIS AND TREATMENT | 2021年 / 7卷

关键词：

Triple negative breast cancer; maintenance therapy; immunotherapy; PARP inhibitor;

D O I：

10.20517/2394-4722.2021.20

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Metastatic triple negative breast cancer (mTNBC) is an aggressive disease associated with a poor prognosis as compared to other subtypes of breast cancer. Significant advances have been made in recent years with new approvals for PARP inhibitors for those patients who harbor germline BRCA mutations and immune checkpoint inhibitors for patients with programmed death ligand-1 (PD-L1) expressing tumors. These therapies are associated with favorable toxicity profiles and improved health-related quality of life when compared with chemotherapy. Maintenance therapy, now recognized as the mainstay for patients with ovarian malignancies, takes advantage of the benefit of low-intensity therapies to suppress a disease over a prolonged period of time following maximal response to induction therapy. This strategy has been little explored in the treatment of mTNBC. Here, we briefly discuss the evidence to date lending credence to this treatment paradigm and examine the potential role of immunotherapy as maintenance in the management of mTNBC.

引用

页数：8

共 31 条

[1] Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial [J].

Bachelot, Thomas ;

Filleron, Thomas ;

Bieche, Ivan ;

Arnedos, Monica ;

Campone, Mario ;

Dalenc, Florence ;

Coussy, Florence ;

Sablin, Marie-Paule ;

Debled, Marc ;

Lefeuvre-Plesse, Claudia ;

Goncalves, Anthony ;

Reynier, Marie-Ange Mouret ;

Jacot, William ;

You, Benoit ;

Barthelemy, Philippe ;

Verret, Benjamin ;

Isambert, Nicolas ;

Tchiknavorian, Xavier ;

Levy, Christelle ;

Thery, Jean-Christophe ;

L'Haridon, Tifenn ;

Ferrero, Jean-Marc ;

Mege, Alice ;

Del Piano, Francesco ;

Rouleau, Etienne ;

Tran-Dien, Alicia ;

Adam, Julien ;

Lusque, Amelie ;

Jimenez, Marta ;

Jacquet, Alexandra ;

Garberis, Ingrid ;

Andre, Fabrice .

NATURE MEDICINE, 2021, 27 (02) :250-+

[2] 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) [J].

Cardoso, F. ;

Paluch-Shimon, S. ;

Senkus, E. ;

Curigliano, G. ;

Aapro, M. S. ;

Andre, F. ;

Barrios, C. H. ;

Bergh, J. ;

Bhattacharyya, G. S. ;

Biganzoli, L. ;

Boyle, F. ;

Cardoso, M-J ;

Carey, L. A. ;

Cortes, J. ;

El Saghir, N. S. ;

Elzayat, M. ;

Eniu, A. ;

Fallowfield, L. ;

Francis, P. A. ;

Gelmon, K. ;

Gligorov, J. ;

Haidinger, R. ;

Harbeck, N. ;

Hu, X. ;

Kaufman, B. ;

Kaur, R. ;

Kiely, B. E. ;

Kim, S-B ;

Lin, N. U. ;

Mertz, S. A. ;

Neciosup, S. ;

Offersen, B., V ;

Ohno, S. ;

Pagani, O. ;

Prat, A. ;

Penault-Llorca, F. ;

Rugo, H. S. ;

Sledge, G. W. ;

Thomssen, C. ;

Vorobiof, D. A. ;

Wiseman, T. ;

Xu, B. ;

Norton, L. ;

Costa, A. ;

Winer, E. P. .

ANNALS OF ONCOLOGY, 2020, 31 (12) :1623-1649

[3] PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer [J].

Chabanon, Roman M. ;

Muirhead, Gareth ;

Krastev, Dragomir B. ;

Adam, Julien ;

Morel, Daphne ;

Garrido, Marlene ;

Lamb, Andrew ;

Henon, Clemence ;

Dorvault, Nicolas ;

Rouanne, Mathieu ;

Marlow, Rebecca ;

Bajrami, Ilirjana ;

Cardenosa, Marta Llorca ;

Konde, Asha ;

Besse, Benjamin ;

Ashworth, Alan ;

Pettitt, Stephen J. ;

Haider, Syed ;

Marabelle, Aurelien ;

Tutt, Andrew N. J. ;

Soria, Jean-Charles ;

Lord, Christopher J. ;

Postel-Vinay, Sophie .

JOURNAL OF CLINICAL INVESTIGATION, 2019, 129 (03) :1211-1228

[4]

Coate Linda E, 2011, Ther Adv Med Oncol, V3, P139, DOI 10.1177/1758834011399306

[5]

Cortes J, 2020, J CLIN ONCOL, V38

[6] Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial [J].

Dieras, Veronique ;

Han, Hyo S. ;

Kaufman, Bella ;

Wildiers, Hans ;

Friedlander, Michael ;

Ayoub, Jean-Pierre ;

Puhalla, Shannon L. ;

Bondarenko, Igor ;

Campone, Mario ;

Jakobsen, Erik H. ;

Jalving, Mathilde ;

Oprean, Cristina ;

Palacova, Marketa ;

Park, Yeon Hee ;

Shparyk, Yaroslav ;

Yanez, Eduardo ;

Khandelwal, Nikhil ;

Kundu, Madan G. ;

Dudley, Matthew ;

Ratajczak, Christine K. ;

Maag, David ;

Arun, Banu K. .

LANCET ONCOLOGY, 2020, 21 (10) :1269-1282

[7] IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab plus nab-paclitaxel vs placebo plus nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer [J].

Emens, L. A. ;

Adams, S. ;

Barrios, C. H. ;

Dieras, V. C. ;

Iwata, H. ;

Loi, S. ;

Rugo, H. S. ;

Schneeweiss, A. ;

Winer, E. P. ;

Patel, S. ;

Henschel, V. ;

Swat, A. ;

Kaul, M. ;

Molinero, L. ;

Chui, S. Y. ;

Schmid, P. .

ANNALS OF ONCOLOGY, 2020, 31 :S1148-S1148

[8] Quality of life with talazoparib versus physician's choice of chemotherapy in patients wits advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA ease III trial [J].

Ettl, J. ;

Quek, R. G. W. ;

Lee, K. -H. ;

Rugo, H. S. ;

Hurvitz, S. ;

Goncalves, A. ;

Fehrenbacher, L. ;

Yerushalmi, R. ;

Mina, L. A. ;

Martin, M. ;

Roche, H. ;

Im, Y. -H. ;

Markova, D. ;

Bhattacharyya, H. ;

Hannah, A. L. ;

Eiermann, W. ;

Blum, J. L. ;

Litton, J. K. .

ANNALS OF ONCOLOGY, 2018, 29 (09) :1939-1947

[9] Weekly Paclitaxel, Capecitabine, and Bevacizumab With Maintenance Capecitabine and Bevacizumab as First-Line Therapy for Triple-Negative, Metastatic, or Locally Advanced Breast Cancer: Results From the GINECO A-TaXel Phase 2 Study [J].

Ferrero, Jean-Marc ;

Hardy-Bessard, Anne-Claire ;

Capitain, Olivier ;

Lortholary, Alain ;

Salles, Bruno ;

Follana, Philippe ;

Herve, Robert ;

Deblock, Mathilde ;

Dauba, Jerome ;

Atlassi, Mustapha ;

Largillier, Remy .

CANCER, 2016, 122 (20) :3119-3126

[10]

Galluzzi L, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000337

← 1 2 3 4 →